JP2019501223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501223A5 JP2019501223A5 JP2018554643A JP2018554643A JP2019501223A5 JP 2019501223 A5 JP2019501223 A5 JP 2019501223A5 JP 2018554643 A JP2018554643 A JP 2018554643A JP 2018554643 A JP2018554643 A JP 2018554643A JP 2019501223 A5 JP2019501223 A5 JP 2019501223A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- group
- alkyl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- -1 methylamino, ethylamino, dimethylamino, diethylamino, N- methyl -N- ethylamino Chemical group 0.000 claims 16
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 9
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 102100022464 5'-nucleotidase Human genes 0.000 claims 2
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 241000406668 Loxodonta cyclotis Species 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 229960005475 antiinfective agent Drugs 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000033133 Testicular seminomatous germ cell tumor Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000010749 gastric carcinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 208000024662 testicular seminoma Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021121236A JP7322104B2 (ja) | 2016-01-08 | 2021-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2023121750A JP7698677B2 (ja) | 2016-01-08 | 2023-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2025099433A JP2025123371A (ja) | 2016-01-08 | 2025-06-13 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276564P | 2016-01-08 | 2016-01-08 | |
| US62/276,564 | 2016-01-08 | ||
| US201662324077P | 2016-04-18 | 2016-04-18 | |
| US62/324,077 | 2016-04-18 | ||
| PCT/US2017/012587 WO2017120508A1 (en) | 2016-01-08 | 2017-01-06 | Modulators of 5'-nucleotidase, ecto and the use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121236A Division JP7322104B2 (ja) | 2016-01-08 | 2021-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501223A JP2019501223A (ja) | 2019-01-17 |
| JP2019501223A5 true JP2019501223A5 (enExample) | 2020-02-13 |
| JP6920344B2 JP6920344B2 (ja) | 2021-08-18 |
Family
ID=59274491
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554643A Active JP6920344B2 (ja) | 2016-01-08 | 2017-01-06 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2021121236A Active JP7322104B2 (ja) | 2016-01-08 | 2021-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2023121750A Active JP7698677B2 (ja) | 2016-01-08 | 2023-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2025099433A Pending JP2025123371A (ja) | 2016-01-08 | 2025-06-13 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121236A Active JP7322104B2 (ja) | 2016-01-08 | 2021-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2023121750A Active JP7698677B2 (ja) | 2016-01-08 | 2023-07-26 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
| JP2025099433A Pending JP2025123371A (ja) | 2016-01-08 | 2025-06-13 | ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US10239912B2 (enExample) |
| EP (2) | EP3399984B1 (enExample) |
| JP (4) | JP6920344B2 (enExample) |
| KR (1) | KR102772803B1 (enExample) |
| CN (3) | CN119912510A (enExample) |
| AU (2) | AU2017206061B2 (enExample) |
| BR (1) | BR112018013827B1 (enExample) |
| CA (2) | CA3009196C (enExample) |
| CL (1) | CL2018001845A1 (enExample) |
| DK (1) | DK3399984T3 (enExample) |
| EA (1) | EA038565B1 (enExample) |
| ES (1) | ES2963759T3 (enExample) |
| FI (1) | FI3399984T3 (enExample) |
| HR (1) | HRP20231155T1 (enExample) |
| HU (1) | HUE063388T2 (enExample) |
| IL (1) | IL260260B2 (enExample) |
| LT (1) | LT3399984T (enExample) |
| MX (2) | MX2018008350A (enExample) |
| MY (1) | MY204877A (enExample) |
| PH (1) | PH12018501361A1 (enExample) |
| PL (1) | PL3399984T3 (enExample) |
| PT (1) | PT3399984T (enExample) |
| SA (1) | SA518391985B1 (enExample) |
| SG (1) | SG11201805506YA (enExample) |
| SI (1) | SI3399984T1 (enExample) |
| TW (2) | TWI744274B (enExample) |
| UA (1) | UA124529C2 (enExample) |
| WO (1) | WO2017120508A1 (enExample) |
| ZA (2) | ZA201804350B (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3399984T (lt) | 2016-01-08 | 2023-11-10 | Arcus Biosciences, Inc. | 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas |
| CN110234656B (zh) | 2016-09-09 | 2023-02-28 | 卡利泰拉生物科技公司 | 外核苷酸酶抑制剂及其使用方法 |
| CN110022881B (zh) * | 2016-11-18 | 2023-05-02 | 艾库斯生物科学有限公司 | Cd73介导的免疫抑制的抑制剂 |
| MA48594B1 (fr) | 2016-12-08 | 2022-05-31 | Hoffmann La Roche | Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a |
| KR102638592B1 (ko) * | 2016-12-22 | 2024-02-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 억제제 및 이의 용도 |
| AU2018235092B2 (en) | 2017-03-16 | 2024-09-19 | Innate Pharma | Compositions and methods for treating cancer |
| US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| AU2018346447B2 (en) | 2017-10-06 | 2025-06-19 | Innate Pharma | Restoration of T cell activity via the CD39/CD73 axis |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN111094317B (zh) * | 2017-12-29 | 2023-03-31 | 上海和誉生物医药科技有限公司 | 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用 |
| TWI702954B (zh) * | 2018-03-01 | 2020-09-01 | 美商美國禮來大藥廠 | Cd73抑制劑 |
| WO2019173682A1 (en) * | 2018-03-09 | 2019-09-12 | Arcus Biosciences, Inc. | Parenterally administered immune enhancing drugs |
| CA3098493A1 (en) * | 2018-04-30 | 2019-11-07 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| TWI870353B (zh) | 2018-06-18 | 2025-01-21 | 法商天賜製藥公司 | 用於治療癌症之組合物及方法 |
| WO2020037275A1 (en) * | 2018-08-17 | 2020-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine and pyrimidine nucleotides as ecto-5'-nucleotidase inhibitors |
| CN112638389A (zh) | 2018-08-28 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | Cd73抑制剂及其治疗用途 |
| US12673969B2 (en) | 2018-09-11 | 2026-07-07 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 inhibitors and pharmaceutical uses thereof |
| MX2021002878A (es) * | 2018-09-11 | 2021-08-16 | Risen Suzhou Pharma Tech Co Ltd | Inhibidores de cd73 y usos farmaceuticos de los mismos. |
| CN110885352B (zh) * | 2018-09-11 | 2023-02-24 | 润佳（苏州）医药科技有限公司 | Cd73抑制剂及其药学应用 |
| US11530234B2 (en) | 2018-09-11 | 2022-12-20 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 inhibitors and pharmaceutical uses thereof |
| EP3893891A4 (en) * | 2018-12-13 | 2022-08-03 | Arcus Biosciences, Inc. | SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE |
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| WO2020151707A1 (zh) * | 2019-01-22 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用 |
| ES3070946T3 (en) * | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) * | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| WO2020205538A1 (en) * | 2019-03-29 | 2020-10-08 | Eternity Bioscience Inc. | Cd73 inhibitors and therapeutic uses thereof |
| WO2020206289A1 (en) * | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| WO2020210938A1 (en) * | 2019-04-15 | 2020-10-22 | Bioardis Llc | Quinazoline derivatives as cd73 inhibitors |
| WO2020210970A1 (en) * | 2019-04-16 | 2020-10-22 | Bioardis Llc | Imidazotriazine derivatives as cd73 inhibitors |
| TWI821559B (zh) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | 一種cd73抑制劑，其製備方法和應用 |
| KR20220034780A (ko) * | 2019-06-14 | 2022-03-18 | 써던 리서취 인스티튜트 | 2,4,7-치환된-7-데아자-2'-데옥시-2'-플루오로아라비노실 뉴클레오사이드 및 뉴클레오타이드 전구약물 및 이의 용도 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| WO2021040356A1 (en) * | 2019-08-23 | 2021-03-04 | Kainos Medicine, Inc. | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition |
| EP4021902B1 (en) * | 2019-08-29 | 2024-03-20 | Eli Lilly and Company | Crystalline forms of a cd73 inhibitor |
| CN116854758A (zh) | 2019-10-30 | 2023-10-10 | 欧瑞克制药公司 | Cd73抑制剂 |
| TW202131932A (zh) * | 2019-11-05 | 2021-09-01 | 美商博奥阿迪斯有限公司 | 作為cd73抑制劑的化合物 |
| US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
| CA3173831A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
| TW202210514A (zh) | 2020-06-02 | 2022-03-16 | 美商阿克思生物科學有限公司 | 針對tigit的抗體 |
| WO2021247188A1 (en) | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Cd73 antagonist potency assay and methods of use thereof |
| CA3179320A1 (en) * | 2020-06-17 | 2021-12-23 | Arcus Biosciences, Inc. | Crystalline forms of a cd73 inhibitor and uses thereof |
| CN115702150A (zh) * | 2020-07-07 | 2023-02-14 | 贝达药业股份有限公司 | Cd73抑制剂及其在医药上的应用 |
| AU2021341258A1 (en) * | 2020-09-08 | 2023-04-13 | Betta Pharmaceuticals Co., Ltd. | CD73 inhibitor and application thereof in medicine |
| CN114437039A (zh) * | 2020-11-05 | 2022-05-06 | 武汉人福创新药物研发中心有限公司 | Cd73抑制剂及其应用 |
| WO2022095953A1 (zh) * | 2020-11-05 | 2022-05-12 | 武汉人福创新药物研发中心有限公司 | 哒嗪炔烃类化合物及其用途 |
| CN114539340B (zh) * | 2020-11-25 | 2024-06-07 | 润佳（苏州）医药科技有限公司 | Cd73抑制剂及其药学应用 |
| CN116546990B (zh) * | 2020-11-25 | 2026-05-26 | 润佳（苏州）医药科技有限公司 | Cd73抑制剂及其药学应用 |
| JP2024502068A (ja) * | 2020-12-29 | 2024-01-17 | チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド | Ａ３アデノシン受容体アゴニスト及びその調製方法と用途 |
| TW202308657A (zh) * | 2021-05-11 | 2023-03-01 | 大陸商四川海思科製藥有限公司 | 小分子cd73拮抗劑及其用途 |
| WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
| EP4341262A1 (en) | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| WO2023061319A1 (zh) * | 2021-10-11 | 2023-04-20 | 南京明德新药研发有限公司 | 三并环杂环衍生物 |
| EP4422643A4 (en) | 2021-10-26 | 2025-11-26 | Southern Res Inst | DEVELOPMENT OF NEW CLOFARABINE ANALOGUES FOR CANCER THERAPY |
| TW202325279A (zh) | 2021-10-29 | 2023-07-01 | 美商阿克思生物科學有限公司 | HIF-2α抑制劑及其使用方法 |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| CN119156228A (zh) | 2022-05-02 | 2024-12-17 | 艾库斯生物科学有限公司 | 抗tigit抗体及其用途 |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN117466964B (zh) * | 2022-07-21 | 2026-05-15 | 南京烁慧医药科技有限公司 | 双磷酸核苷类化合物及其制备方法 |
| TW202421150A (zh) | 2022-09-14 | 2024-06-01 | 美商阿克思生物科學有限公司 | 艾魯美冷之分散體 |
| US20240140979A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| US20240140980A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| CN120091809A (zh) | 2022-10-20 | 2025-06-03 | 艾库斯生物科学有限公司 | Cd73化合物的冻干制剂 |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN117924394B (zh) * | 2023-09-05 | 2026-07-24 | 厦门大学 | 核苷酸类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物 |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| EP4788432A1 (en) | 2023-10-06 | 2026-08-12 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US12384773B2 (en) | 2023-11-02 | 2025-08-12 | Arcus Biosciences, Inc. | Thiazole compounds and methods of use thereof |
| WO2025113498A1 (zh) * | 2023-12-01 | 2025-06-05 | 无锡和誉生物医药科技有限公司 | 一种cd73抑制剂碱式盐及其制备方法和应用 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5569650A (en) * | 1993-06-11 | 1996-10-29 | Sloan-Kettering Institute For Cancer Research | C-nucleoside isosters of analogs thereof and pharmaceutical compositions |
| AU4815197A (en) * | 1996-10-09 | 1998-05-05 | Pharmasset, Ltd. | Tetraphosphonate bicyclic trisanhydrides |
| JP2005502580A (ja) * | 2000-12-15 | 2005-01-27 | フアーマセツト・リミテツド | フラビウィルス感染治療用抗ウィルス薬 |
| WO2012032513A1 (en) * | 2010-09-07 | 2012-03-15 | Bar-Ilan University | Boranophosphate derivatives for the treatment of osteoarthritis |
| WO2013132489A1 (en) * | 2012-03-05 | 2013-09-12 | Bar-Ilan University | Nucleoside 5'-phosphorothioate analogues and uses thereof |
| AU2013257951A1 (en) * | 2012-05-11 | 2015-01-22 | Akron Molecules Ag | Use of compounds for the treatment of pain |
| US9090697B2 (en) | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| FR3011240A1 (fr) * | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| KR20200029627A (ko) * | 2014-03-12 | 2020-03-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
| EP3134411B1 (en) * | 2014-04-25 | 2021-06-30 | Boehringer Ingelheim International GmbH | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| CN107922409A (zh) | 2015-08-17 | 2018-04-17 | 鲁宾有限公司 | 作为parp抑制剂的杂芳基衍生物 |
| TWI782395B (zh) | 2016-01-08 | 2022-11-01 | 美商西建公司 | 抗增生化合物，及其醫藥組合物及用途 |
| LT3399984T (lt) * | 2016-01-08 | 2023-11-10 | Arcus Biosciences, Inc. | 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas |
| UY37062A (es) | 2016-01-08 | 2017-08-31 | Syngenta Participations Ag | Derivados de aryl oxadiazol fungicidas |
| WO2019173682A1 (en) | 2018-03-09 | 2019-09-12 | Arcus Biosciences, Inc. | Parenterally administered immune enhancing drugs |
| EP3893891A4 (en) | 2018-12-13 | 2022-08-03 | Arcus Biosciences, Inc. | SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE |
| US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
| CA3179320A1 (en) | 2020-06-17 | 2021-12-23 | Arcus Biosciences, Inc. | Crystalline forms of a cd73 inhibitor and uses thereof |
-
2017
- 2017-01-06 LT LTEPPCT/US2017/012587T patent/LT3399984T/lt unknown
- 2017-01-06 EP EP17736459.3A patent/EP3399984B1/en active Active
- 2017-01-06 TW TW106100542A patent/TWI744274B/zh active
- 2017-01-06 CN CN202411958636.7A patent/CN119912510A/zh active Pending
- 2017-01-06 JP JP2018554643A patent/JP6920344B2/ja active Active
- 2017-01-06 HR HRP20231155TT patent/HRP20231155T1/hr unknown
- 2017-01-06 EP EP23194905.8A patent/EP4306525A3/en active Pending
- 2017-01-06 SG SG11201805506YA patent/SG11201805506YA/en unknown
- 2017-01-06 TW TW110136486A patent/TW202227095A/zh unknown
- 2017-01-06 UA UAA201808490A patent/UA124529C2/uk unknown
- 2017-01-06 KR KR1020187022597A patent/KR102772803B1/ko active Active
- 2017-01-06 MX MX2018008350A patent/MX2018008350A/es unknown
- 2017-01-06 IL IL260260A patent/IL260260B2/en unknown
- 2017-01-06 PT PT177364593T patent/PT3399984T/pt unknown
- 2017-01-06 CN CN202210014893.XA patent/CN114395005B/zh active Active
- 2017-01-06 BR BR112018013827-4A patent/BR112018013827B1/pt active IP Right Grant
- 2017-01-06 US US15/400,748 patent/US10239912B2/en active Active
- 2017-01-06 HU HUE17736459A patent/HUE063388T2/hu unknown
- 2017-01-06 ES ES17736459T patent/ES2963759T3/es active Active
- 2017-01-06 WO PCT/US2017/012587 patent/WO2017120508A1/en not_active Ceased
- 2017-01-06 CA CA3009196A patent/CA3009196C/en active Active
- 2017-01-06 PL PL17736459.3T patent/PL3399984T3/pl unknown
- 2017-01-06 EA EA201891583A patent/EA038565B1/ru unknown
- 2017-01-06 CN CN201780006172.1A patent/CN108697719B/zh active Active
- 2017-01-06 SI SI201731439T patent/SI3399984T1/sl unknown
- 2017-01-06 FI FIEP17736459.3T patent/FI3399984T3/fi active
- 2017-01-06 AU AU2017206061A patent/AU2017206061B2/en active Active
- 2017-01-06 CA CA3151595A patent/CA3151595A1/en active Pending
- 2017-01-06 MY MYPI2018001218A patent/MY204877A/en unknown
- 2017-01-06 DK DK17736459.3T patent/DK3399984T3/da active
-
2018
- 2018-06-25 PH PH12018501361A patent/PH12018501361A1/en unknown
- 2018-06-28 ZA ZA2018/04350A patent/ZA201804350B/en unknown
- 2018-07-05 MX MX2022006322A patent/MX2022006322A/es unknown
- 2018-07-05 SA SA518391985A patent/SA518391985B1/ar unknown
- 2018-07-05 CL CL2018001845A patent/CL2018001845A1/es unknown
-
2019
- 2019-02-12 US US16/273,843 patent/US10981944B2/en active Active
-
2020
- 2020-09-01 US US17/009,590 patent/US11001603B2/en active Active
-
2021
- 2021-03-19 US US17/206,896 patent/US11667662B2/en active Active
- 2021-07-26 JP JP2021121236A patent/JP7322104B2/ja active Active
-
2022
- 2022-08-24 ZA ZA2022/09472A patent/ZA202209472B/en unknown
-
2023
- 2023-03-02 AU AU2023201288A patent/AU2023201288B2/en active Active
- 2023-07-26 JP JP2023121750A patent/JP7698677B2/ja active Active
- 2023-11-21 US US18/516,459 patent/US12459967B2/en active Active
-
2025
- 2025-06-13 JP JP2025099433A patent/JP2025123371A/ja active Pending
- 2025-09-25 US US19/340,533 patent/US20260146059A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021167351A5 (enExample) | ||
| JP2019529500A5 (enExample) | ||
| JP2019535720A5 (enExample) | ||
| JP2021531314A5 (enExample) | ||
| JP2017537080A5 (enExample) | ||
| HRP20231155T1 (hr) | Modulatori 5'-nukleotidaze, ecto i njihova uporaba | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| ME03804B (me) | Karbamoiloksimetil triazol cikloheksilne kiseline kao antagonisti lpa | |
| HRP20231157T1 (hr) | Azolopirimidin za liječenje poremećaja povezanih s rakom | |
| JP2017538677A5 (enExample) | ||
| JP2020111618A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| HRP20191799T1 (hr) | 1h-pirazolo[3,4-b]piridini i njihova terapeutska uporaba | |
| JP2021532162A5 (enExample) | ||
| JP2013529196A5 (enExample) | ||
| JP2017528467A5 (enExample) | ||
| JP2013525458A5 (enExample) | ||
| JP2021501756A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2020519664A5 (enExample) | ||
| JP2014525464A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2011511095A5 (enExample) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2019527718A5 (enExample) |